{"id":61119,"title":"Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study.","abstract":"","date":"2014-07-28","categories":"Hemic and Lymphatic Diseases","split":"train","url":"http://www.ncbi.nlm.nih.gov/pubmed/24761968","annotations":[{"name":"Clinical trial","weight":0.346584,"wikipedia_article":"http://en.wikipedia.org/wiki/Clinical_trial"},{"name":"Bortezomib","weight":0.115812,"wikipedia_article":"http://en.wikipedia.org/wiki/Bortezomib"},{"name":"Rituximab","weight":0.108635,"wikipedia_article":"http://en.wikipedia.org/wiki/Rituximab"},{"name":"Lymphoma","weight":0.104316,"wikipedia_article":"http://en.wikipedia.org/wiki/Lymphoma"},{"name":"Tumor","weight":0.0494293,"wikipedia_article":"http://en.wikipedia.org/wiki/Tumor"},{"name":"Frontline (U.S. TV series)","weight":0.0297972,"wikipedia_article":"http://en.wikipedia.org/wiki/Frontline_(U.S._TV_series)"},{"name":"Phase (waves)","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Phase_(waves)"},{"name":"Therapy","weight":0.0141339,"wikipedia_article":"http://en.wikipedia.org/wiki/Therapy"}]}
